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A large share of hepatitis C virus amino acid sequence variation is concentrated within two hypervariable regions located at the N-terminus of
the E2 envelope glycoprotein (HVR1 and HVR2). Interhost and intrahost comparison of 391 E2 sequences derived from 17 subjects infected with
HCV using amino acid entropy revealed clustering of amino acid variability at a third site (residues 431–466), which was termed HVR3. Genetic
distance analysis supported the division of HVR3 into three subdomains (HVR3a, HVR3b, and HVR3c). Study of synonymous and
nonsynonymous nucleic acid substitutions confirmed that HVR3a was subjected to strong intrahost-selective pressure. Physicochemical and
antigenicity predictions, conservation of key residues, and molecular modeling were concordant with one another and further validated the
proposed organization of HVR3. Taken together, these results are suggestive of a role for HVR3 in cell surface receptor binding and viral entry
akin to that proposed for HVR1 and HVR2.
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Hepatitis C virus (HCV) is an enveloped RNA virus be-
longing to the Flaviviridae family (Choo et al., 1989, 1991).
Despite the fact that some infected individuals are able to clear
the virus, more than 80% become chronically infected and may
develop liver cirrhosis and hepatocellular carcinoma (Saito et al.,
1990; Alter et al., 1992; Bach et al., 1992). Hepatitis C is a
leading cause of liver transplantation and represents a continuing⁎ Corresponding author. Unité d'immunopathologie virale, Centre de
recherche du CHU mère-enfant Sainte-Justine, 3175 Côte Sainte-Catherine,
room 6735, Montreal, Quebec, Canada H3T 1C5. Fax: +1 514 345 4794.
E-mail address: hugo.soudeyns@recherche-ste-justine.qc.ca (H. Soudeyns).
1 Present address: INRS-Institut Armand-Frappier, Laval, Quebec, Canada
H7V 1B7.
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.05.015public health concern. There is currently no vaccine to prevent
HCV infection.
As a result of common modes of transmission, the global
prevalence of HCV infection among human immunodeficiency
virus type 1 (HIV-1)-infected subjects ranges between 30%
and 50%, with rates of coinfection as high as 90% in injection
drug users and almost 100% in patients with hemophilia
(Dieterich, 1999; Dodig and Tavill, 2001). Several studies
have shown that coinfection with HCV and HIV-1 adversely
affects liver fibrosis, HCV viral load, and progression of HCV
disease (Soriano et al., 1999; Bonacini and Puoti, 2000;
Benhamou et al., 2001).
The high genetic variability of HCV contributes to the chro-
nicity of hepatitis C. Based on nucleotide sequence analysis,
HCV was classified into 6 genotypes and a series of subtypes
(Simmonds et al., 1993, 2005). Moreover, in individual subjects,
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related variants designated quasispecies (Martell et al., 1992;
Bukh et al., 1995). HCV quasispecies evolution is influenced
mainly by (a) the high production rate of viral particles; (b) the
lack of error correction mechanisms by viral RNA-dependent
RNA polymerase; and (c) selective pressure exerted by host
immune responses. The HCVE2 viral envelope glycoprotein is a
preferred target for humoral (Weiner et al., 1992; Kato et al.,
1993) and cell-mediated immune responses (Shirai et al., 1999).
Not surprisingly, a large share of HCV sequence variation is
concentrated within the hypervariable regions of E2, including
hypervariable region 1 (HVR1), a sequence of 27 amino acids
located at the N-terminus of the protein (Weiner et al., 1991;
Kato et al., 1992). The conservation of overall conformation and
positively charged amino acid residues at specific positions of
HVR1 are consistent with a role in target cell recognition and
virus attachment (Penin et al., 2001). HVR1 exhibits the highest
degree of intersequence variability in the HCV genome and
constitute a practical model for the study of host-selective
pressure and quasispeciation; that is, the process of viral genetic
diversification leading to quasispecies formation following clo-
nal infection (Sala and Wain-Hobson, 2000). Quasispecies dy-
namics based on HVR1 are indicative of outcomes such as
spontaneous viral clearance (Farci et al., 2000; Chen and Wang,
2005), response to interferon treatment (Farci et al., 2002; Gaudy
et al., 2003; Abbate et al., 2004), and HCV-associated liver
histopathology (Honda et al., 1994; Gonzalez-Peralta et al.,
1996). The second hypervariable region of E2, HVR2, consists
of 9 amino acids located downstream of HVR1 (Kato et al.,
1992). In this case, structure predictions are consistent with a
potential involvement in cell surface receptor binding (Yagnik
et al., 2000). Here, we report on the identification of an
additional highly variable region in HCV glycoprotein E2,
which we termed HVR3. Quasispecies diversity was studied inFig. 1. Amino acid sequence diversity in HCV E1–E2 envelope glycoproteins. Variab
E1–E2 sequences derived from third trimester samples from all study subjects and th
methods. Amino acid positions correspond to the M62321 reference sequence (Choo
with previous reports (Weiner et al., 1991; Kato et al., 1992).order to determine whether HVR3 was potentially subjected to
selective pressure exerted by host HCV specific immunity, and
the physicochemical and structural characteristics of this region
were evaluated to gain insights into its possible functional roles.
Results
Identification and characterization of HVR3
HCV E1 and E2 envelope gene sequences were amplified
starting with serial serum samples (pregestational; 1st, 2nd, 3rd
trimesters; postpartum) obtained from 17 pregnant women in-
fectedwithHCV,including13whowerecoinfectedwithHCVand
HIV-1. Four women were studied throughout two conscutive
pregnancies. Nine patients were infected with HCV genotype 1a,
5withHCVgenotype 1b, and 3withHCVgenotype 3a.A total of
1337 nucleic acid sequences (570–576 nucleotides) were
obtained, including 1101 that were nonredundant, representing
a mean of 78.7 sequences per patient (range = 52–147).
Nucleotide sequences were edited and translated, spanning
amino acid positions 319–508 of theHCV-1a reference sequence
(GenBankaccessionno.M62321),andcorrespondingto the65C-
terminal amino acid residues of E1 and the 125N-terminal amino
acid residues of E2 (E1/128–E2/125).
First, for the purposes of estimating amino acid sequence
diversity, a data set comprised of all 391 E1–E2 sequences
derived from third trimester samples from all patients was
assembled, of which 331 (84.7%) were nonredundant at the
nucleic acid level, representing a mean of 23 sequences per
patient (range = 17–38). Hence, this data set simultaneously
sampled roughly equivalent contributions from both intrahost
and interhost E1–E2 amino acid sequence diversity. Amino acid
sequences were aligned, and the entropy or variability at each
position of the alignment was determined (Fig. 1). The entropyility at each amino acid position was computed using a data set comprised of 391
e Entropy-ONE Web tool (Korber et al., 1994), as described under Materials and
et al., 1989). Boundaries of E1, E2, HVR1, and HVR2 were set in accordance
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distributed across the amplified E1–E2 segments, with visually
discernible clusters of amino acid sequence diversity. The first
cluster (amino acid positions 384–410) was well defined and
corresponded to the 27 amino acids of HVR1 (Weiner et al.,
1991), whereas a second cluster, further downstream (amino
acid positions 474–482), corresponded to HVR2 (Kato et al.,
1992). Interestingly, distribution of amino acid entropy in the
region between HVR1 and HVR2 (amino acid positions 411–
473) was clearly discontinuous, and a third cluster of amino acid
variability was readily delineated, spanning amino acid positions
431–466, approximately halfway between HVR1 and HVR2
(Fig. 1). For the purpose of the present study, we termed this
region HVR3. HVR3 was empirically subdivided into two re-
gions of roughly equal size, which were termed HVR3a (amino
acid positions 431–449) and HVR3b (amino acid positions
450–466). Additional sequence variation was observed at the N
terminus and C terminus of the amplified segment (Fig. 1).
Analysis was focused on HVR3 because (a) the first 65 N-
terminal amino acids are in fact localized within the C-terminal
portion of the E1 envelope protein; and (b) amino acids at the C
terminus are localized at the extreme end of our sequence reads,
where base miscalls are more prevalent. The overall entropy
profile was not affected by removal from the alignment of all
HCV-3a sequences (n = 58; subjects TV453, TVC45, and
TVC73) and/or all sequences from patient TV531 (n = 17), who
respectively exhibited a 1 and 2 amino acid insertion between
positions 476 and 477 (data not shown). Likewise, comparable
amino acid entropy profiles were obtained when analysis was
performed with (a) additional subsamples from the complete
1337 sequence data set (Troesch et al., unpublished); or (b) a set
of 187 full-length genomic HCV sequences comprising all 6
major HCV subtypes (http://hcv.lanl.gov/content/hcv-db/; Kui-
ken et al., 2005) (Supplemental Fig. 1; data not shown).
To test relative amino acid sequence variability, genetic
distances were estimated within each of these domains and
subdomains (Table 1). As expected, highest variability was
observed at the positions corresponding to HVR1 and HVR2.
Mean genetic distance was lower in HVR3 (431–466) than inTable 1










E1/128–E2/125 319–508 0.253 0.020
HVR1 384–410 0.509 0.049
HVR2 474–482 0.541 0.044
HVR3 431–466 0.315 0.042
HVR3a 431–449 0.305 0.056
HVR3b 450–466 0.326 0.061
HVR3c 456–466 0.430 0.064
Nucleic acid sequences were obtained, edited, translated, and analyzed as des-
cribed under Materials and methods.
a Amino acid positions correspond to the M62321 reference sequence (Choo
et al., 1989).
b Mean genetic distance was calculated as mean of pairwise p distances.
c Standard error of the mean was computed by bootstrapping (500 replicates)
(Kumar et al., 2001).HVR1 or HVR2 but higher than that obtained when the com-
plete E1/128–E2/125 segment was analyzed (Table 1). Within
HVR3, the HVR3b subdomain was comparatively more va-
riable than HVR3a or than the whole of HVR3. Additional
truncation of the HVR3b subdomain into HVR3c (amino acid
positions 456–466) circumscribed a region of high sequence
diversity, with a mean genetic distance of 0.430 ± 0.064 (Fig. 1).
These values represented 84.5% and 79.5% of the mean genetic
distances measured within HVR1 and HVR2, respectively, and
170% of the mean variability observed in the complete E1/128–
E2/125 region (Table 1). Again, none of these estimates was
adversely affected by exclusion of all HCV-3a sequences and/or
sequences from patient TV531 (see above), and all were com-
parable to those obtained using a set of 187 full-length genomic
HCV sequences retrieved from the Los Alamos database
(Kuiken et al., 2005) (Supplemental Table 1; data not shown).
Intrahost selective pressure
Next, the presence and extent of intrahost selective pressure
exerted on HCV E2 sequences were examined within gene
segments encoding the HVR1, HVR2, HVR3, HVR3a, HVR3b,
and HVR3c subdomains, which showed the highest amino acid
variability when initial interhost comparisons were performed
(Table 1). To do this, we assembled data sets comprised of
nucleic acid sequences derived from longitudinal samples ob-
tained from each patient throughout pregnancy (pregestational;
1st, 2nd, 3rd trimesters; postpartum). The ratio of the mean
number of nonsynonymous substitutions per nonsynonymous
site over the mean number of synonymous substitutions per
synonymous site (dN/dS) was then computed within the above-
mentioned E1–E2 subdomains, with a dN/dS ratio >1 taken as an
index of positive selection for specific amino acid residues (Nei
and Gojobori, 1986). As HVR3 and HVR3c represented broadly
overlapping and/or nested subregions, comparisons of dN/dS
ratios were not drawn that involved either of these regions.
Finally, it should be noted that the Los Alamos data set essen-
tially samples interhost not intrahost variability (i.e., all of these
sequences are presumably unrelated). The extent of intrahost-
selective pressure can therefore not be computed using such a
data set.
Overall, statistically significant differences in median dN/dS
ratio were observed between subregions in multiple group ana-
lysis (P = 0.0002, Kruskal–Wallis test). As expected, median
dN/dS ratio for HVR1 (2.391; interquartile range (IQR) = 0.816–
3.092) was significantly higher than that observed in HVR2
(0.227; IQR = 0.089–0.858), HVR3b (0.204; IQR = 0.129–
0.330), but not HVR3a (0.719; IQR = 0.280–1.120) (P < 0.01,
P < 0.001, and P > 0.05, respectively, Dunn's multiple com-
parison test) (Table 2). Thirteen of 17 HCV-infected subjects
tested (76.5%) had a dN/dS ratio >1 in HVR1, as compared with
6 of 17 (35.3%) in HVR3a, 2 of 17 (11.8%) in HVR2, and 1 of 17
(5.88%) in HVR3b (Table 2). In addition, 10 of 17 HCV-infected
subjects (58.8%) exhibited statistically significant positive
selection in HVR1 in analysis of variance (P < 0.10, Z test), as
compared with 2 of 17 (11.8%) in HVR3a, 1 of 17 (5.88%) in
HVR2, and 0 of 17 (0%) in HVR3b (Table 2). These results are
Table 2


















TVC57 − 1a 2.614 b, c 0.090 0.812 1.177 b 0.424 2.812 b, c
TVC67 − 1a 1.482 b 0.163 0.607 0.634 0.498 0.246
TVC75 − 1b 1.181 b 0.227 0.282 0.395 0.163 0.151
TVC79 − 1a 3.826 b, c 0.000 0.513 1.542 b 0.174 0.119
TV075 d + 1a 0.081 0.024 0.110 0.041 0.340 0.766
TV179 d + 1b 0.136 7.317 b, c 0.202 0.164 0.204 0.163
TV233 d + 1b 2.743 b, c 0.175 0.685 3.825 b, c 0.096 0.180
TV289 + 1b 2.391 b, c nc 0.461 0.431 1.549 b 1.283 b
TV453 + 3a 0.428 0.166 0.037 0.023 0.052 0.037
TV519 + 1b 4.263 b, c nc 0.552 1.062 b 0.044 0.204
TV531 + 1a 1.860 b, c 0.253 0.391 0.955 0.233 0.521
TVC17 + 1a 3.975 b, c 2.191 b 1.182 b 4.674 b, c 0.320 1.592 b
TVC33 + 1a 3.054 b, c 0.515 0.558 1.036 b 0.289 0.210
TVC45 + 3a 1.040 b 0.858 0.626 0.904 0.227 0.345
TVC55d + 1a 2.724 b, c 0.965 0.363 0.693 0.173 0.283
TVC59 + 1a 0.592 0.248 0.165 0.139 0.185 0.220
TVC73 + 3a 3.131 b, c 0.065 0.383 0.719 0.088 0.314
Nucleic acid sequencing, HCV genotyping, and calculation of the dN/dS ratio were performed as described under Materials and methods.
a Amino acid positions correspond to the M62321 reference sequence (Choo et al., 1989).
b Denotes dN > dS.
c Denotes significant positive selection as determined by analysis of variance (P < 0.10, Z test) (Kumar et al., 2001). nc: not computed due to absence of
synonymous substitutions in that particular sequence subset.
d Analysis performed on two consecutive pregnancies.
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principal foci of intrahost immune-selective pressure (Weiner
et al., 1992; Kato et al., 1993; Farci et al., 2000, 2002; Canobio
et al., 2004). These results also indicate that HVR3a (residues
431–449) was the second most highly selected subdomain after
HVR1 within the E2 region examined, and HVR3b was the least
selected. Overall, this observed hierarchy in positive subdomain
selection provides experimental support for the amino acid
entropy and genetic distance-based clustering approach initially
used to define HVR3, HVR3a, HVR3b, and HVR3c (Fig. 1;
Table 1; Supplemental Fig. 1; Supplemental Table 1). Interest-
ingly, linear regression analysis revealed a statistically signifi-
cant relationship between the dN/dS ratios computed in HVR1
and HVR3a (r2 = 0.360, P = 0.0105). However, there were no
such significant relationships observed that involved either
HVR2 or HVR3b. These results suggest that the selective forces
that shape the amino acid sequences of HVR1 and HVR3a act in
a similar and/or synchronous manner on both subregions,
whereas genetic diversification in HVR2 and HVR3b would
appear to be driven by distinct selective forces.
Influence of HCV subtype and coinfection with HIV-1
Three subjects in our study group (TV453, TVC45, and
TCV73) were infected with HCV-3a, a subtype that not only
displays marked amino acid sequence dissimilarity as compared
with HCV-1a and HCV-1b, but also exhibits variant biological
properties in terms of pathogenesis and resistance to interferon
treatment (Pawlotsky, 2000; Rubbia-Brandt et al., 2001). For
these reasons, intrahost-selective pressure was examined sepa-
rately in these subjects.Median dN/dS ratio was lower in patientsinfected with HCV-3a than HCV-1a or HCV-1b for all
subdomains analyzed (Table 2). Within HVR1, 2 of 3 subjects
(66.6%) with HCV-3a infection displayed a dN/dS ratio >1, and
1 of 3 (33.3%) exhibited significant positive selection as
determined by analysis of variance (Table 2). These proportions
were similar to those observed in subjects infected with HCV-1a
or HCV-1b with respect to HVR1 and all other E2 subdomains,
but the statistical significance of these observations was not
tested due to the limited number of HCV-3a-infected subjects
enrolled in our study group.
In addition, a number of studies have reported that infection
with human immunodeficiency virus type 1 (HIV-1) influenced
HCV quasispecies distribution and reduced host-selective pres-
sure exerted on HVR1 in coinfected subjects (Sherman et al.,
1996; Mao et al., 2001; Canobio et al., 2004). Because of this,
intrahost-selective pressure on HVR1, HVR2, HVR3a, and
HVR3b was compared between HCV/HIV-1 coinfected patients
(n = 14) and patients infected solely with HCV (n = 4). Overall,
the median dN/dS ratio was not significantly higher in subjects
infected only with HCV than in coinfected patients (P > 0.117,
Mann–Whitney U test), and there was no significant difference
in the proportion of coinfected subjects exhibiting either a dN/dS
ratio >1 or significant positive selection for any of the E2
subdomains analyzed (P > 0.235, Fisher's exact test).
Physicochemical properties and predicted antigenicity of
HVR3
Because HVR3, and in particular HVR3a, stood out as HCV
E2 envelope glycoprotein subregions subjected to relatively high
intrahost selective pressure, details of their physicochemical
361M. Troesch et al. / Virology 352 (2006) 357–367properties and predicted antigenicity profiles were further in-
vestigated. This analysis was based on an HVR3 consensus
sequence of 36 amino acid residues (DSLNTGFLAGLFYY-
HKFNSSGCPERLASCRPITDFA) derived from the 391 third
trimester E1–E2 sequences (see above and Table 1). According
to the Kyte and Doolittle (1982) method, HVR3 displays a rather
hydrophilic central region located within the C-terminal portion
of HVR3a, whereas its flanks (i.e., N-terminal HVR3a, HVR3b)
are generally hydrophobic (Fig. 2A). The Parker index, which
integrates hydrophilicity, atomic flexibility, and HPLC retention
components, remains one of the most extensively validated in
silico predictors of protein antigenicity (Parker et al., 1986).
Computing of this index over the HVR3 consensus sequence
revealed two salient peaks of antigenicity, both locatedwithin the
C-terminal part of HVR3a and both overlapping regions of
relatively high hydrophilicity highlighted in the Kyte–Doolittle
plot (Figs. 2A and B). These regions also overlapped with
segments predicted to be highly surface-exposed by the Janin
accessibility method (Fig. 2C) (Janin, 1979). Overall, combina-
tion of these prediction algorithms suggests that the main
antigenic portion of HVR3 lies within HVR3a, and positions
HVR3a at the surface of E2, where it should be accessible and
recognizable by antibodies. These observations further validate
the HVR3a, HVR3b, and HVR3c subdomain organization
initially proposed on the basis of amino acid sequence entropy
and genetic distance.
Detailed examination of the amino acid sequence compo-
sition of HVR3a revealed a domain comprised of relatively
conserved hydrophobic residues surrounded by relatively hydro-
philic or neutral amino acids (Fig. 3). Thus, in spite of the
relative amino acid sequence variability observed within this
region, its overall hydropathic character appears highly con-
served, both in interhost and intrahost comparisons (Fig. 3). In
particular, amino acid positions 433, 437, 438, 439, 441, 442,Fig. 2. Physicochemical properties and antigenic characterization of HVR3. Physicoc
trimester samples were computed using the NPS@ webware (http://npsa-pbil.ibcp.f
(Parker et al., 1986). (C) Accessibility profile (Janin, 1979).443, and 447 were almost exclusively held by hydrophobic
residues. Positions 432, 435, and 436 were occupied by neutral
residues, with a fully invariant glycine at position 436. The
remaining positions were held by hydrophilic (431, 434, 445,
446, and 448) or variable amino acids (440, 444, and 449) (Fig.
3). Overall, positions of highest amino acid sequence variability
within HVR3a overlapped those of predicted antigenic sites
(Fig. 2B). Positively charged residues were mainly found C-
terminal from the hydrophobic center (positions 445 and 446 in
81.0% and 93.3% of sequences, respectively) and to a lesser
extent at position 444 (7.44%). Position 434 exhibited both
positively and negatively charged residues, with a preference for
basic amino acids (28.0% versus 10.0%). Interestingly, the first
position of HVR3a (residue 431) was almost always occupied by
a basic residue. Fully consistent profiles were observed when
analysis was performed using a set of 187 full-length genomic
HCV sequences from the Los Alamos HCV sequence database
(data not shown) (Kuiken et al., 2005). The conservation of
hydrophobic amino acids and charged residues suggests that the
overall conformation of HVR3a is likewise conserved among
HCV variants comprised within the quasispecies.
Molecular modeling of HVR3
The tick-borne encephalitis virus (TBEV) E protein, which is
distantly related to HCV envelope glycoproteins, remains the
closest available crystal structure amenable to three-dimension-
al modeling of E2 (Rey et al., 1995). Work using this model has
led to the formulation of several testable hypotheses regarding
E1–E2 structure, higher order organization, immunogenicity,
and function (Yagnik et al., 2000; Slater-Handshy et al., 2004;
Heo et al., 2004). This model was reconstructed by incorporating
the consensus amino acid sequence of HVR3 derived from
alignment of the 391 third trimester E1–E2 sequences describedhemical profiles of the consensus HVR3 amino acid sequence derived from third
r). (A) Hydropathicity plot (Kyte and Doolittle, 1982). (B) Antigenicity index
Fig. 3. Amino acid usage in HVR3a. The range of amino acid residues that occupy each position of HVR3a was determined from a data set comprised of 391 E1–E2
sequences derived from third trimester samples from all study subjects. HI: hydrophilic; N: neutral; HO: hydrophobic. Amino acid positions correspond to the M62321
reference sequence (Choo et al., 1989).
362 M. Troesch et al. / Virology 352 (2006) 357–367above. Confirming antigenicity and accessibility predictions,
HVR3 was found to be very largely exposed at the surface of E2,
with a potential contact surface of approximately 800Å2 and
50% of HVR3 amino acids having more than 30% of their total
surface exposed (Fig. 4). In fact, the only amino acid residuesFig. 4. Molecular modeling of hepatitis C virus E2 envelope glycoprotein. (A)
Schematic representation of the E2 protein of HCV with hypervariable regions
highlighted. (B and C) Surface of the E2 protein based on tick-borne encephalitis
virus E protein crystal structure (front and reverse side shown) (Rey et al., 1995;
Yagnik et al., 2000). Blue: hypervariable region 1 (HVR1); red: hypervariable
region 2 (HVR2); orange: hypervariable region 3c (HVR3c); orange and pink:
hypervariable region 3b (HVR3b); orange, pink, and green: hypervariable
region 3 (HVR3).that appear to be entirely buried within the structure are
phenylalanine 437 and leucine 438 (0% exposure), which are
primarily hidden underneath cysteine 503 and glycine 504,
whereas alanine 439 and glycine 440 have <5% exposure. In this
three-dimensional model, HVR3 lies distal to the proposed
dimerization interface (Rey et al., 1995). HVR3 is also strikingly
distant from HVR1, which is situated at the opposite end of E2
and largely positioned on the other face of the protein. This
structural arrangement would make direct interactions between
these two domains improbable, both in the context of
monomeric and dimeric envelope structures. In contrast, and
most interestingly, HVR3c is in close spatial proximity with
HVR2: the apex of HVR2 (GSG tripeptide) and the center of
HVR3c (RPL tripeptide) are separated by an estimated distance
of 27Å, whereas the closest point-to-point distance between
HVR2 and HVR3 is only 9Å.
Discussion
HCV E1 and E2 envelope glycoproteins are of particular
interest because of their central implication in the initial steps of
viral infection and because they constitute important targets for
the host's HCV-specific immune responses. Herein we report
that significant clustering of interhost genetic diversity takes
place outside of already-described E2 hypervariable regions
HVR1 and HVR2. In addition to HVR1 and HVR2, amino acid
sequence variability was particularly striking within HVR3 as a
whole (amino acid positions 431–466) and HVR3c (amino acid
positions 456–466). Evidence was also provided that these
newly described envelope subdomains were subjected to diffe-
rential levels of intrahost selective pressure. Indeed, positive
selection, as expressed by the mean dN/dS ratio, was highest in
HVR1 > HVR3a > HVR2 > HVR3b. In fact, the dN/dS ratio
was higher in HVR3a than HVR2 in 13 of 17 patients (76.5%)
examined in the present study (Table 2). Interhost genetic di-
versity and intrahost selection pressure were not strictly
dependent on HCV genotype: these parameters were indistin-
guishable in subjects infected with HCV-1a, HCV-1b, or HCV-
3a, even though the limited number of subjects examined per
stratum may have obscured the detection of subtle differences in
363M. Troesch et al. / Virology 352 (2006) 357–367this regard. Interestingly, interhost genetic variability and
intrahost selective pressure were not focalized on identical E2
subdomains, with the exception of HVR1, which was both
highly diversified and subjected to robust positive selection.
Furthermore, significant correlation between the dN/dS ratios
observed in HVR1 and HVR3a, but not HVR3b and HVR2, is
potentially reflective of functional differences between respec-
tive subdomains (see below).
Intrahost selective pressure can be exerted at least in part
by host HCV-specific immune responses, and humoral immu-
nity is an important component of this response. Indeed,
neutralizing monoclonal antibodies 1/39, 2/69a, 7/16b, and 11/
20, that block the binding of HCV-like particles to human CD81
and inhibit infection of Huh-7.5 hepatoma cells by HIV
pseudotyped particles bearing native HCV E1 and E2, bind
within a 15 amino acids region of glycoprotein E2 (amino acid
residues 432–447) that maps precisely to HVR3a (Flint et al.,
1999; Owsianka et al., 2001; Hsu et al., 2003). In addition, we
cannot exclude that cell-mediated immune responses, in par-
ticular class I MHC-restricted cytotoxic T lymphocytes (CTL),
also play a role in exerting selective pressure on particular HVR3
segments. Multiple CTL epitopes were described in E2, includ-
ing some located within hypervariable regions (Shirai et al.,
1999; Frasca et al., 1999; Tester et al., 2005). In particular, the
HLA-B53-restricted epitope CRPLTDFDQGV maps to the C-
terminal part of HVR3c (Wong et al., 1998), whereas the E2–21
peptide (DFAQGWGPISYANGS), that straddles the C-terminal
part of HVR3c and the N-terminal part of HVR2, is recognized
by CD8+ T cells in HCV-infected subjects expressing HLA-A2,
B15, and B51 (Dutoit et al., 2005). Moreover, positive selection
associated with CTL escape was observed in acute and chronic
HCV infection (Timm et al., 2004; Cox et al., 2005) and could
serve to explain interhost and intrahost amino acid sequence
variability at positions occupied by hydrophobic residues (i.e.,
amino acid positions 437 and 438) that were predicted to be
largely buried within E2 based on molecular modeling (Fig. 4).
HIV infection induces a decline in CD4+ T cell numbers and,
as a consequence, can result in suppression of HCV-specific
immune responses in coinfected hosts (Lauer et al., 2002).
Consistent with this principle, several groups of investigators
have shown that coinfection of HCV+ subjects with HIV-1 led
to a modulation of HCV quasispecies evolution and to reduced
intrahost selective pressure on HVR1 (Mao et al., 2001;
Canobio et al., 2004). However, in the present study, a
significant reduction in host selective pressure exerted on E2
was not observed in coinfected subjects, as compared with
patients infected with HCValone. This can be explained by the
fact that mean CD4+ T cell counts in coinfected study
participants were >500 cells/mm3, with only 2 subjects below
the 200 cells/mm3 AIDS-defining threshold. These values are
not consistent with substantial HIV-associated immunosuppres-
sion. Hence, a marked reduction in selective pressure would not
be anticipated. As well, 11 of 13 coinfected subjects were
treated with antiretroviral therapy during the course of the study,
including 10 who were treated with combinations of antire-
troviral agents. This commonly leads to a rapid restoration of
CD4+ T cell counts and of functional immunocompetence(Autran et al., 1997). In fact, the two lowermost dN/dS ratios
observed in HVR1 during the course of the study were observed
in TV075 and TV179, two coinfected subjects who were not
initially treated with antiretrovirals.
In summary, data were presented that supports the existence
in HCV E2 of a third hypervariable region located between
HVR1 and HVR2. Concordance between results of the amino
acid entropy-based clustering approach (Fig. 1), interhost ge-
netic distance comparisons (Table 1), intrahost selective
pressure data (Table 2), secondary structure, antigenicity, and
accessibility predictions (Fig. 2), and three-dimensional molec-
ular modeling (Fig. 4) provides compelling evidence in support
of the proposed HVR3 subdomain organization. Taken together,
these data also suggest that (a) at least sizable portions of HVR3,
including the C-terminal part of HVR3a, are being exposed at
the surface of E2; (b) consistent with monoclonal antibody
binding, HVR3, including HVR3a, can be targeted by host
humoral immune responses; and (c) consistent with antibody
neutralization experiments, HVR3 plays a role in the process of
binding with host cell receptors and entry of the virus into host
cells. In this regard, whereas amino acid sequence variation
observed in HVR3a was extensive in some cases, the basic
organization and physicochemical characteristics of residues at
key positions in HVR3a were generally well-conserved (Fig. 3).
In particular, further analysis showed that the hydropathic
profile at the center of HVR3a was conserved among genotypes
(data not shown), suggestive of functional constraints on
variation potentially related to conformational conservation of
the E2 glycoprotein, viral fitness, and/or specific subdomain
function. Likewise, the conserved positive charges localized
within the rather hydrophilic environment at the edge of the
hydrophobic center of HVR3a represents a feature conserved
across genotypes that suggests a functional role of this region,
for instance in protein–protein interaction. Amino acid residues
proximal to HVR2 have been implicated in binding of E2 to the
CD81 cell surface molecule, an interaction that has strong
potential relevance for viral entry of HCV in the host cell and the
pathogenesis of hepatitis C (Pileri et al., 1998; Hsu et al., 2003).
Molecular modeling (Fig. 4) revealed that HVR3c and, to a
certain extent, HVR3a and HVR3b, were closely clustered in the
E2 envelope glycoprotein structure, suggestive of a potential
role in binding of putative HCV cell surface receptors, including
CD81, scavenger receptor class B type I (SR-BI) (Scarselli et al.,
2002), and/or heparan sulfate (Barth et al., 2003). Alternatively,
a region corresponding to HVR3a was recently reported to
contain a fusion peptide-like domain (amino acid positions
436–443; GWLAGLFY) homologous to that found in TBEV,
dengue virus, and other flaviviruses, which would have bipartite
functions in binding CD81 and mediating fusion of the viral and
host cell membranes (Drummer et al., 2005). It is tempting to
speculate that neighboring HVR3b, which shows marked amino
acid sequence diversity in interhost comparisons but appears
subjected to little if any intrahost selection, could be
functionally involved in pH-dependent conformational changes
in E2, leading to exposure of this putative fusion peptide.
However, resolution of these issues will need to await direct
experimentation.
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future investigations into HCV envelope function and HCV
envelope-specific immune responses should take into account
the full extent of amino acid sequence variability of the E2
glycoprotein, which clearly extends beyond HVR1 and HVR2.
In addition, because of the high levels of interhost sequence
variability observed outside of HVR1, cross-sectional studies
based on comparisons of selective pressure in HVR1 and so-
called invariant flanking regions should be interpreted with
caution. A fuller understanding of the structure–function rela-
tionships in HCV envelope glycoproteins will contribute to the
design of HCVentry inhibitors and may lead to the development
of immunogens to prevent and/or treat hepatitis C.
Materials and methods
Patients and clinical parameters
Study subjects (n = 17) were selected among participants to
the CentreMaternel et Infantile sur le SIDAmother–child cohort
(CHU mère-enfant Sainte-Justine, Montreal, Canada) and were
previously enrolled in a study of immune responses and HCV
quasispecies evolution during pregnancy (Troesch et al., un-
published). This study was conducted according to the Decla-
ration of Helsinki, and the research protocol was approved by the
Ethics Review Board of CHU mère-enfant Sainte-Justine,
Montreal, Canada. All patients and their children were provided
with medical care and counseling required by their condition.
Mean age at study entry was 27.9 years (range = 22.2–40.7
years). Four of the subjects were infected with HCVonly and 13
were coinfected with HCV and HIV-1, as determined using
standard diagnostic algorithms routinely applied in the Province
of Quebec. At the time of the study, all coinfected patients were
treated with combination antiretroviral therapy for the purpose
of preventing mother-to-child transmission of HIV-1, with the
exception of subjects TV075 and TV179, who were only treated
during the second of two consecutive pregnancies analyzed.
In coinfected subjects, mean CD4+ and CD8+ T lymphocyte
counts, measured by flow cytometry, were 558 cells/mm3
(range = 144–1287 cells/mm3) and 731 cells/mm3 (range =
431–1122 cells/mm3), respectively. Serum was extracted from
whole blood by centrifugation and kept at −80 °C until used.
HCV genotyping was performed by sequence analysis of the 5′
noncoding region and NS5B, as described (Murphy et al., 1994).
RNA extraction, RT-PCR, cDNA cloning and sequencing
RNA was extracted from 280 μl serum according to the
QIAamp Viral RNA protocol and cDNAwas synthesized using
the OneStep RT-PCR method (QIAGEN, Mississauga,
Canada). A portion of the E1 and E2 genes from HCV geno-
type 1 (nucleotide positions 1278–1889) was amplified by RT-
PCR, with the nucleotide sequence of HCV-1a used as reference
(GenBank accession no. M62321). Amplification was carried
out using primers E2/NS1a (5′-ATA ACG GGT CAC CGC
ATG GCATGG GATAT-3′) and E2/NS1b (5′-CAC CAC CAC
GGGGCT GGGAGT GAAGCA AT-3′) (Farci et al., 2000). Inthe case of patient TVC55, primers E2/NS5aBIS (5′-GGC ATG
GGA CAT GAT GAT GA-3′) and E2/NS1b were used (nucleo-
tide positions 1295–1889). In the case of subjects infected with
HCV genotype 3, primers E2/NS3a (5′-TGT ACC CAG GCC
ATC TTT CA-3′) and E2/NS1b or E2/NS3b (5′-ATC AGT
AGT GCC TAC GAC CA-3′) were used (nucleotide positions
1262–1890 or 1262–1902, respectively), with the nucleotide
sequence of HCV-3a serving as reference (GenBank accession
no. D17763). Reverse transcription was performed at 50 °C for
30 min. The PCR reaction consisted of 40 cycles of denaturing
at 94 °C for 50 s, annealing at 55 °C for 1 min, and extension at
72 °C for 1 min. The fact that the enzyme used was not a
proofreading polymerase would have for effect to increase the
observed mutation rate. However, this increase will be largely
unbiased with respect to the localization of mutations within the
amplified segments, and comparisons between various subloci
located within a single amplicons should therefore remain valid
(Polyak et al., 2005). PCR products were purified from agarose
gels using the GFX system (Amersham Biosciences, Piscat-
away, NJ). Amplicons were cloned between the twin EcoRI
sites of pCR2.1-TOPO and were transformed into Escherichia
coli TOP10-competent cells (Invitrogen, Carlsbad, CA). Plas-
mid DNA from transformants was extracted and purified with
the Perfectprep Plasmid 96 Vac Direct Bind System (Eppendorf,
Hamburg, Germany). Unidirectional sequencing of recombi-
nants was performed on a Genetic Analyser 3100 (Applied
Biosystems, Foster City, CA) using dye terminator chemistry.
Sequence analysis
Chromatogramswereeditedmanually (Chromasversion1.45,
Technelysium, Southport, Australia). All nucleotide sequences
were submitted to GenBank (accession nos. DQ650805–
DQ652141). Sequence alignments were visualized, compared,
and edited using ClustalX version 1.81 (Thompson et al., 1997).
Variability at each amino acid position was calculated as the






) is the pro-
bability of a given amino acid (s) appearing at a given position
(i). Entropy was computed and consensus amino acid sequence
was determined using the Entropy-ONE Web tool (http://hcv.
lanl.gov/content/hcv-db/ENTROPY) (Korber et al., 1994).
Mean genetic distance, defined as the mean of all pairwise p
distance comparisons (number of amino acid differences divided
by the total number of amino acid sites compared), and its
standard deviation were calculated using MEGA version 2.1
(Kumar et al., 2001). The number of nonsynonymous (amino
acid replacement) nucleotide substitutions per nonsynonymous
site (dN), the number of synonymous (silent) nucleotide
substitution per synonymous site (dS), and the dN/dS ratio
were computed according to the Nei–Gojobori method with the
Jukes–Cantor correction (Nei and Gojobori, 1986). dN/dS was
expressed as median and interquartile range (IQR), and the
significance of positive selection was determined using analysis
of variance (Z test), as implemented in MEGA 2.1 (Kumar et al.,
2001). As dN/dS does not follow the Gaussian distribution
(Kolmogorov–Smirnov test), the Kruskal–Wallis test for mul-
tiple groups was selected for comparisons between medians.
365M. Troesch et al. / Virology 352 (2006) 357–367Comparisons between regions were examined using Dunn's
post test, which corrects for multiple comparisons in nonpara-
metric tests.
Molecular modeling of HCV E2 glycoprotein
The model of E2 was generated essentially as described by
Yagnik and coworkers (2000). Briefly, secondary structure
predictions were used to align HCV E2 with the sequence of the
E envelope glycoprotein of TBEV. The alignment generated was
used to model the E2 protein using the structure of the TBEV E
protein (PDB code 1SVB; Rey et al., 1995) and theMODELLER
program (Sali and Blundell, 1993). Energy minimization of the
resulting model was then performed using 100 steps of the
steepest descents algorithm with the consistent valence force
field (CVFF) (Dauber-Osguthorpe et al., 1988). The protein
structure was analyzed with the Swiss PDB Viewer 3.7 program
(Guex and Peitsch, 1997), and the final images were rendered
using POVRAYversion 3.5.
Acknowledgments
The authors wish to thank Martine Caty, Silvie Valois, and
Ampha Khammy for expert technical assistance, and Marc-
André Rodrigue and Julie Lacaille for automated DNA
sequencing. Supported by grants from the CIHR-Health Canada
Research Initiative on Hepatitis C (grant no. EOP-41537),
CANFAR-Canadian Foundation for AIDS Research (grant no.
013515), and The Elizabeth Glaser Pediatric AIDS Foundation
(grant no. 28-PG-51355). M.T. was the recipient of a scho-
larship from Fondation de l'Hôpital Sainte-Justine. H.S. is a
Junior-II Scientist of le Fonds de la recherche en santé du
Québec (FRSQ).
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.virol.2006.05.015.References
Abbate, I., Lo Iacono, O., Di Stefano, R., Cappiello, G., Girardi, E., Longo, R.,
Ferraro, D., Antonucci, G., Di Marco, V., Solmone, M., Craxi, A., Ippolito,
G., Capobianchi, M.R., 2004. HVR-1 quasispecies modifications occur
early and are correlated to initial but not sustained response in HCV-
infected patients treated with pegylated- or standard-interferon and riba-
virin. J. Hepatol. 40, 831–836.
Alter, M.J., Margolis, H.S., Krawczynski, K., Judson, F.N., Mares, A.,
Alexander, W.J., Hu, P.Y., Gerber, M.A., Sampliner, R.E., Meeks, E.L.,
Beach, M.J., 1992. The natural history of community-acquired hepatitis C in
the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis
Study Team. N. Engl. J. Med. 327, 1899–1905.
Autran, B., Carcelain, G., Li, T.S., Blanc, C., Mathez, D., Tubiana, R., Katlama,
C., Debre, P., Leibowitch, J., 1997. Positive effects of combined
antiretroviral therapy on CD4+ T cell homeostasis and function in advanced
HIV disease. Science 277, 112–116.
Bach, N., Thung, S.N., Schaffner, F., 1992. The histological features of chronic
hepatitis C and autoimmune chronic hepatitis: a comparative analysis.
Hepatology 15, 572–577.Barth, H., Schafer, C., Adah, M.I., Zhang, F., Linhardt, R.J., Toyoda, H.,
Kinoshita-Toyoda, A., Toida, T., Van Kuppevelt, T.H., Depla, E., Von
Weizsacker, F., Blum, H.E., Baumert, T.F., 2003. Cellular binding of
hepatitis C virus envelope glycoprotein E2 requires cell surface heparan
sulfate. J. Biol. Chem. 278, 41003–41012.
Benhamou, Y., Di Martino, V., Bochet, M., Colombet, G., Thibault, V., Liou, A.,
Katlama, C., Poynard, T., 2001. Factors affecting liver fibrosis in human
immunodeficiency virus- and hepatitis C virus-coinfected patients: impact of
protease inhibitor therapy. Hepatology 34, 283–287.
Bonacini, M., Puoti, M., 2000. Hepatitis C in patients with human
immunodeficiency virus infection: diagnosis, natural history, meta-analysis
of sexual and vertical transmission, and therapeutic issues. Arch. Intern.
Med. 160, 3365–3373.
Bukh, J., Miller, R.H., Purcell, R.H., 1995. Genetic heterogeneity of hepatitis C
virus: quasispecies and genotypes. Semin. Liver Dis. 15, 41–63.
Canobio, S., Guilbert, C., Troesch, M., Samson, J., Lemay, M., Pelletier, V.A.,
Bernard-Bonnin, A.C., Kozielski, R., Lapointe, N., Martin, S.R., Soudeyns,
H., 2004. Differing patterns of liver disease progression and hepatitis C virus
(HCV) quasispecies evolution in children vertically coinfectedwithHCVand
human immunodeficiency virus type 1. J. Clin. Microbiol. 42, 4365–4369.
Chen, S., Wang, Y.M., 2005. Multigene tracking of quasispecies in viral
persistence and clearance of hepatitis C virus. World J. Gastroenterol. 11,
2874–2884.
Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M.,
1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B
viral hepatitis genome. Science 244, 359–362.
Choo, Q.L., Richman, K.H., Han, J.H., Berger, K., Lee, C., Dong, C., Gallegos,
C., Coit, D., Medina-Selby, R., Barr, P.J., Weiner, A.J., Bradley, D.W., Kuo,
G., Houghton, M., 1991. Genetic organization and diversity of the hepatitis
C virus. Proc. Natl. Acad. Sci. U.S.A. 88, 2451–2455.
Cox, A.L., Mosbruger, T., Mao, Q., Liu, Z., Wang, X.H., Yang, H.C., Sidney, J.,
Sette, A., Pardoll, D., Thomas, D.L., Ray, S.C., 2005. Cellular immune
selection with hepatitis C virus persistence in humans. J. Exp. Med. 201,
1741–1752.
Dauber-Osguthorpe, P., Roberts, V.A., Osguthorpe, D.J., Wolff, J., Genest, M.,
Hagler, A.T., 1988. Structure and energetics of ligand binding to proteins:
Escherichia coli dihydrofolate reductase-trimethoprim, a drug-receptor
system. Proteins 4, 31–47.
Dieterich, D.T., 1999. Hepatitis C virus and human immunodeficiency virus:
clinical issues in coinfection. Am. J. Med. 107, 79S–84S.
Dodig, M., Tavill, A.S., 2001. Hepatitis C and human immunodeficiency virus
coinfections. J. Clin. Gastroenterol. 33, 367–374.
Drummer, H., Maerz, A., Poumbourios, P., 2005. Structural and functional role
of a fusion-peptide like sequence in hepatitis C virus glycoprotein E2.
Abstracts of the 12th International Meeting on HCV and Related Viruses,
Montreal, Canada, p. 26.
Dutoit, V., Ciuffreda, D., Comte, D., Gonvers, J.J., Pantaleo, G., 2005.
Differences in HCV-specific T cell responses between chronic HCV
infection and HIV/HCV co-infection. Eur. J. Immunol. 35, 3493–3504.
Farci, P., Shimoda, A., Coiana, A., Diaz, G., Peddis, G., Melpolder, J.C.,
Strazzera, A., Chien, D.Y., Munoz, S.J., Balestrieri, A., Purcell, R.H., Alter,
H.J., 2000. The outcome of acute hepatitis C predicted by the evolution of
the viral quasispecies. Science 288, 339–344.
Farci, P., Strazzera, R., Alter, H.J., Farci, S., Degioannis, D., Coiana, A., Peddis,
G., Usai, F., Serra, G., Chessa, L., Diaz, G., Balestrieri, A., Purcell, R.H.,
2002. Early changes in hepatitis C viral quasispecies during interferon
therapy predict the therapeutic outcome. Proc. Natl. Acad. Sci. U.S.A. 99,
3081–3086.
Flint, M., Maidens, C., Loomis-Price, L.D., Shotton, C., Dubuisson, J., Monk,
P., Higginbottom, A., Levy, S., McKeating, J.A., 1999. Characterization of
hepatitis C virus E2 glycoprotein interaction with a putative cellular
receptor, CD81. J. Virol. 73, 6235–6244.
Frasca, L., Del Porto, P., Tuosto, L., Marinari, B., Scotta, C., Carbonari, M.,
Nicosia, A., Piccoletta, E., 1999. Hypervariable region 1 variants act as TCR
antagonists for hepatitis C virus-specific CD4+ T cells. J. Immunol. 163,
650–658.
Gaudy, C., Moreau, A., Veillon, P., Temoin, S., Lunel, F., Goudeau, A., 2003.
Significance of pretreatment analysis of hepatitis C virus genotype 1b
366 M. Troesch et al. / Virology 352 (2006) 357–367hypervariable region 1 sequences to predict antiviral outcome. J. Clin.
Microbiol. 41, 3615–3622.
Gonzalez-Peralta, R.P., Qian, K., She, J.Y., Davis, G.L., Ohno, T., Mizokami,
M., Lau, J.Y., 1996. Clinical implications of viral quasispecies heterogeneity
in chronic hepatitis C. J. Med. Virol. 49, 242–247.
Guex, N., Peitsch, M.C., 1997. SWISS-MODEL and the Swiss-PdbViewer: an
environment for comparative protein modeling. Electrophoresis 18,
2714–2723.
Heo, T.H., Chang, J.H., Lee, J.W., Foung, S.K.H., Dubuisson, J., Kang, C.Y.,
2004. Incomplete humoral immunity against hepatitis C virus is linked with
distinct recognition of putative multiple receptors by E2 envelope
glycoproteins. J. Immunol. 173, 446–455.
Honda, M., Kaneko, S., Sakai, A., Unoura, M., Murakami, S., Kobayashi, K.,
1994. Degree of diversity of hepatitis C virus quasispecies and progression
of liver disease. Hepatology 20, 1144–1151.
Hsu, M., Zhang, J., Flint, M., Logvinoff, C., Cheng-Mayer, C., Rice, C.M.,
McKeating, J.A., 2003. Hepatitis C virus glycoproteins mediate pH-
dependent cell entry of pseudotyped viral particles. Proc. Natl. Acad. Sci.
U.S.A. 100, 7271–7276.
Janin, J., 1979. Surface and inside volumes in globular proteins. Nature 277,
491–492.
Kato, N., Ootsuyama, Y., Tanaka, T., Nakagawa, M., Nakazawa, T., Muraiso,
K., Ohkoshi, S., Hijikata, M., Shimotohno, K., 1992. Marked sequence
diversity in the putative envelope proteins of hepatitis C viruses. Virus Res.
22, 107–123.
Kato, N., Sekiya, H., Ootsuyama, Y., Nakazawa, T., Hijikata, M., Ohkoshi, S.,
Shimotohno, K., 1993. Humoral immune response to hypervariable region 1
of the putative envelope glycoprotein (gp70) of hepatitis C virus. J. Virol.
67, 3923–3930.
Korber, B.T.M., Kunstman, K.J., Patterson, B.K., Furtado, M., McEvilly,
M.M., Levy, R., Wolinsky, S.M., 1994. Genetic differences between
blood- and brain-derived viral sequences from human immunodeficiency
virus type 1-infected patients: evidence of conserved elements in the V3
region of the envelope protein of brain-derived sequences. J. Virol. 68,
7467–7481.
Kuiken, C., Yusim, K., Boykin, L., Richardson, R., 2005. The Los Alamos HCV
sequence database. Bioinformatics 21, 379–384.
Kumar, S., Tamura, K., Jakobsen, I.B., Nei, M., 2001. MEGA2: molecular
evolutionary genetics analysis software. Bioinformatics 17, 1244–1245.
Kyte, J., Doolittle, R.F., 1982. A simple method for displaying the hydropathic
character of a protein. J. Mol. Biol. 157, 105–132.
Lauer, G.M., Nguyen, T.N., Day, C.L., Robbins, G.K., Flynn, T., McGowan, K.,
Rosenberg, E.S., Lucas, M., Klenerman, P., Chung, R.T., Walker, B.D.,
2002. Human immunodeficiency virus type 1-hepatitis C virus coinfection:
intraindividual comparison of cellular immune responses against two
persistent viruses. J. Virol. 76, 2817–2826.
Mao, Q., Ray, S.C., Laeyendecker, O., Ticehurst, J.R., Strathdee, S.A., Vlahov,
D., Thomas, D.L., 2001. Human immunodeficiency virus seroconversion
and evolution of the hepatitis C virus quasispecies. J. Virol. 75, 3259–3267.
Martell, M., Esteban, J.I., Quer, J., Genesca, J., Weiner, A., Esteban, R.,
Guardia, J., Gomez, J., 1992. Hepatitis C virus (HCV) circulates as a
population of different but closely related genomes: quasispecies nature of
HCV genome distribution. J. Virol. 66, 3225–3229.
Murphy, D., Willems, B., Delage, G., 1994. Use of the 5′ noncoding region for
genotyping hepatitis C virus. J. Infect. Dis. 169, 473–475.
Nei, M., Gojobori, T., 1986. Simple methods for estimating the numbers of
synonymous and nonsynonymous nucleotide substitutions. Mol. Biol. Evol.
3, 418–426.
Owsianka, A., Clayton, R.F., Loomis-Price, L.D., McKeating, J.A., Patel, A.H.,
2001. Functional analysis of hepatitis C virus E2 glycoproteins and virus-
like particles reveals structural dissimilarities between different forms of E2.
J. Virol. 82, 1877–1883.
Parker, J.M., Guo, D., Hodges, R.S., 1986. New hydrophilicity scale derived
from high-performance liquid chromatography peptide retention data:
correlation of predicted surface residues with antigenicity and X-ray-derived
accessible sites. Biochemistry 25, 5425–5432.
Pawlotsky, J.M., 2000. Hepatitis C virus resistance to antiviral therapy.
Hepatology 32, 889–896.Penin, F., Combet, C., Germanidis, G., Frainais, P.O., Deleage, G., Pawlotsky,
J.M., 2001. Conservation of the conformation and positive charges of
hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a
role in cell attachment. J. Virol. 75, 5703–5710.
Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R.,
Weiner, A.J., Houghton, M., Rosa, D., Grandi, G., Abrignani, S., 1998.
Binding of hepatitis C virus to CD81. Science 282, 938–941.
Polyak, S.J., Sullivan, D.G., Austin, M.A., Dai, J.Y., Shunhart, M.C., Lindsay,
K.L., Bonkovsky, H.L., Di Bisceglie, A.M., Lee, W.M., Morishima, C.,
Gretch, D.R., 2005. Comparison of amplification enzymes for hepatitis C
virus quasispecies analysis. Virol J 2, 41.
Rey, F.A., Heinz, F.X., Mandl, C., Kunz, C., Harrison, S.C., 1995. The envelope
glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature
375, 291–298.
Rubbia-Brandt, L., Leandro, G., Spahr, L., Giostra, E., Quadri, R., Male, P.J.,
Negro, F., 2001. Liver steatosis in chronic hepatitis C: a morphological
sign suggesting infection with HCV genotype 3. Histopathology 39,
119–124.
Saito, I., Miyamura, T., Ohbayashi, A., Harada, H., Katayama, T., Kikuchi,
S., Watanabe, Y., Koi, S., Onji, M., Ohta, Y., Choo, Q.L., Houghton, M.,
Kuo, G., 1990. Hepatitis C virus infection is associated with the
development of hepatocellular carcinoma. Proc. Natl. Acad. Sci. U.S.A.
87, 6547–6549.
Sala, M., Wain-Hobson, S., 2000. Are RNA viruses adapting or merely
changing? J. Mol. Evol. 51, 12–20.
Sali, A., Blundell, T.L., 1993. Comparative protein modelling by satisfaction of
spatial restraints. J. Mol. Biol. 234, 779–815.
Scarselli, E., Ansuini, H., Cerino, R., Roccasecca, R.M., Acali, S., Filocamo, G.,
Traboni, C., Nicosia, A., Cortese, R., Vitelli, A., 2002. The human scavenger
receptor class B type I is a novel candidate receptor for the hepatitis C virus.
EMBO J. 21, 5017–5025.
Sherman, K.E., Andreatta, C., O'Brien, J., Gutierrez, A., Harris, R., 1996.
Hepatitis C in human immunodeficiency virus-coinfected patients: increased
variability in the hypervariable envelope coding domain. Hepatology 23,
688–694.
Shirai, M., Arichi, T., Chen, M., Masaki, T., Nishioka, M., Ikeda, K., Takahashi,
H., Enomoto, N., Saito, T., Major, M.E., Nakazawa, T., Akatsuka, T.,
Feinstone, S.M., Berzofsky, J.A., 1999. T cell recognition of hypervariable
region-1 from hepatitis C virus envelope protein with multiple class II MHC
molecules in mice and humans: preferential help for induction of antibodies
to the hypervariable region. J. Immunol. 162, 568–576.
Simmonds, P., Holmes, E.C., Cha, T.A., Chan, S.W., McOmish, F., Irvine,
B., Beall, E., Yap, P.L., Kolberg, J., Urdea, M.S., 1993. Classification
of hepatitis C virus into six major genotypes and a series of subtypes
by phylogenetic analysis of the NS-5 region. J. Gen. Virol. 74,
2391–2399.
Simmonds, P., Bukh, J., Combet, C., Deleage, G., Enomoto, N., Feistone, S.,
Halfon, P., Inchauspe, G., Kuiken, C., Maertens, G., Mizokami, M., Murphy,
D.G., Okamoto, H., Pawlotsky, J.M., Penin, F., Sablon, E., Shin-I, T.,
Stuyver, L.J., Thiel, H.J., Viazov, S., Weiner, A.J., Widell, A., 2005.
Consensus proposals for a unified system of nomenclature of hepatitis C
virus genotypes. Hepatology 42, 962–973.
Slater-Handshy, T., Droll, D.A., Di Bisceglie, A.M., Chambers, T.J., 2004. HCV
E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects
on E2 expression and processing. Virology 319, 36–48.
Soriano, V., Rodriguez-Rosado, R., Garcia-Samaniego, J., 1999. Management
of chronic hepatitis C in HIV-infected patients. AIDS 13, 539–546.
Tester, I., Smyk-Pearson, S., Wang, P., Wertheimer, A., Yao, E., Lewinsohn,
D.M., Tavis, J.E., Rosen, H.R., 2005. Immune evasion versus recovery
after acute hepatitis C virus infection from a shared source. J. Exp. Med.
201, 1725–1731.
Thompson, J.D., Gibson, T.J., Plewniak, F., Jeanmougin, F., Higgins, D.G.,
1997. The ClustalX windows interface: flexible strategies for multiple
sequence alignment aided by quality analysis tools. Nucleic Acids Res. 25,
4876–4882.
Timm, J., Lauer, G.M., Kavanagh, D.G., Sheridan, I., Kim, A.Y., Lucas, M.,
Pillay, T., Ouchi, K., Reyor, L.L., Zur Wiesch, J.S., Gandhi, R.T., Chung,
R.T., Bhardwaj, N., Klenerman, P., Walker, B.D., Allen, T.M., 2004. CD8
367M. Troesch et al. / Virology 352 (2006) 357–367epitope escape and reversion in acute HCV infection. J. Exp. Med. 200,
1593–1604.
Weiner, A.J., Brauer, M.J., Rosenblatt, J., Richman, K.H., Tung, J., Crawford,
K., Bonino, F., Saracco, G., Choo, Q.L., Houghton, M., 1991. Variable and
hypervariable domains are found in the regions of HCV corresponding to
the flavivirus envelope and NS1 proteins and the pestivirus envelope
glycoproteins. Virology 180, 842–848.
Weiner, A.J., Geysen, H.M., Christopherson, C., Hall, J.E., Mason, T.J.,
Saracco, G., Bonino, F., Crawford, K., Marion, C.D., Crawford, K.A.,
Brunetto, M., Barr, P.J., Miyamura, T., McHutchinson, J., Houghton, M.,1992. Evidence for immune selection of hepatitis C virus (HCV) putative
envelope glycoprotein variants: potential role in chronic HCV infections.
Proc. Natl. Acad. Sci. U.S.A. 89, 3468–3472.
Wong, D.K., Dudley, D.D., Afdhal, N.H., Dienstag, J., Rice, C.M., Wang, L.,
Houghton, M., Walter, B.D., Koziel, M.J., 1998. Liver-derived CTL in
hepatitis C virus infection: breadth and specificity of responses in a cohort of
persons with chronic infection. J. Immunol. 160, 1479–1488.
Yagnik, A.T., Lahm, A., Meola, A., Roccasecca, R.M., Ercole, B.B., Nicosia,
A., Tramontano, A., 2000. A model for the hepatitis C virus envelope
glycoprotein E2. Proteins 40, 355–366.
